{"url":"https://newsforagent.com/news/2026-11-10/inovio-pharmaceuticals-q3-2026-results-voceryq","markdown_url":"https://newsforagent.com/news/2026-11-10/inovio-pharmaceuticals-q3-2026-results-voceryq.md","title":"Inovio Pharmaceuticals Posts Q3 2026 Results","headline":"Inovio Pharmaceuticals Reports Q3 2026 Results and $80.5 Million Offering After First DNA Medicine Approval","description":"Inovio Pharmaceuticals reported a Q3 2026 net loss of $49.2 million and $80.5 million in offering proceeds.","section":"Earnings & Results","published_at":"2026-11-10T21:27:13+00:00","modified_at":"2026-11-10T21:27:13+00:00","author":"News Desk","key_takeaways":["Inovio Pharmaceuticals reported a third-quarter 2026 net loss of $49.2 million, or $0.50 per share.","The FDA granted accelerated approval to VOCERYQ on October 30, 2026, for adults with recurrent respiratory papillomatosis.","Inovio raised $80.5 million in net proceeds from a public offering to support the VOCERYQ commercial launch."],"companies":[{"name":"Inovio Pharmaceuticals","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0002rsx/inovio-pharmaceuticals","website":"http://www.inovio.com"},{"name":"Syneos Health","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0000rsi/syneos-health","website":"https://www.syneoshealth.com"}],"source":{"publisher":"PR Newswire","title":"INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights","url":"https://www.prnewswire.com/news-releases/inovio-reports-third-quarter-2026-financial-results-and-recent-business-highlights-302935492.html"},"other_sources":[],"tags":["Earnings & Results","Inovio Pharmaceuticals","Syneos Health"],"body_markdown":"Inovio Pharmaceuticals reported a third-quarter 2026 net loss of $49.2 million, or $0.50 per basic and diluted share, and said it expects VOCERYQ to be available to order and ship in about 60 days, with a full commercial launch in the first quarter of 2027. The company announced the results on November 10, 2026, according to [PR Newswire](https://www.prnewswire.com/news-releases/inovio-reports-third-quarter-2026-financial-results-and-recent-business-highlights-302935492.html).\n\n## Inovio's VOCERYQ Approval and Launch Plans\n\n[Inovio Pharmaceuticals](https://akta.pro/company-profiles/0002rsx/inovio-pharmaceuticals) is a commercial-stage biotechnology company developing DNA medicines for HPV-related diseases, cancer and infectious diseases. The FDA granted accelerated approval to VOCERYQ on October 30, 2026, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). The approval was based on a complete response, defined as no requirement for surgical intervention in the 12 months after treatment, in the efficacy population of the RRP-001 study, which evaluated the therapy in 32 adult patients across multiple clinical sites.\n\n\"We are delighted with the recent approval of VOCERYQ, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms,\" said Dr. Jacqueline Shea, Inovio's President and Chief Executive Officer. \"Our recently completed public offering provides additional financial resources to support a successful launch.\"\n\nInovio said it has engaged [Syneos Health](https://akta.pro/company-profiles/0000rsi/syneos-health) to support the recruitment and deployment of its medical and commercial field teams. Syneos Health opened a 137,000-sq-ft Global Life Sciences and Technology Centre in Hyderabad in September 2026, its largest in Asia and third-largest globally, according to Business Standard.\n\n## Inovio's Third-Quarter 2026 Financials\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Inovio has raised a total of $599.9 million, with its most recent funding round a $20 million post-IPO equity in July 2026. The company's research and development expenses fell to $10.6 million in the third quarter of 2026 from $13.3 million a year earlier, while selling, general and administrative expenses rose to $9.2 million from $7.9 million. Total operating expenses decreased to $19.8 million from $21.2 million.\n\n## Inovio's Path to the VOCERYQ Approval\n\nIn March 2026, Inovio announced a 16% workforce reduction ahead of the pending INO-3107 FDA decision, according to akta.pro company records. In October 2026, a court decision awarded Inovio almost $62 million in compensatory damages and $19 million for fees and costs, American City Business Journals reported. On November 2, 2026, Inovio said its four-dose treatment for RRP would be available in about 60 days, with the price set at $115,000 per dose, American City Business Journals reported.\n\n## What Comes Next for Inovio\n\nInovio expects to submit a draft protocol for a confirmatory study of VOCERYQ to the FDA by the end of 2026, with the expectation of aligning on a final protocol by mid-2027. The company also plans to submit an application for conditional marketing authorization for VOCERYQ in Europe before the end of 2026.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}